tradingkey.logo
搜尋

Journey Medical Corp

DERM
添加自選
6.250USD
-0.080-1.26%
收盤 05/18, 16:00美東報價延遲15分鐘
134.59M總市值
虧損本益比TTM

Journey Medical Corp

6.250
-0.080-1.26%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.26%

5天

+25.00%

1月

+15.96%

6月

-21.38%

今年開始到現在

-18.94%

1年

-9.88%

TradingKey Journey Medical Corp股票評分

單位: USD 更新時間: 2026-05-18

操作建議

Journey Medical Corp當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名39/155位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為13.50。中期看,股價處於下降通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Journey Medical Corp評分

相關信息

行業排名
39 / 155
全市場排名
107 / 4479
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Journey Medical Corp亮點

亮點風險
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
業績增長期
公司處於發展階段,最新年度總收入61.86M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入61.86M美元
估值合理
公司最新PE估值-17.05,處於3年歷史合理位
機構加倉
最新機構持股12.08M股,環比增加18.49%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉11.34K股

分析師目標

基於 4 分析師
買入
評級
13.500
目標均價
+113.27%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Journey Medical Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Journey Medical Corp簡介

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
公司代碼DERM
公司Journey Medical Corp
CEOMaraoui (Claude)
網址https://journeymedicalcorp.com/
KeyAI